Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. November 2013 16:05 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences to Host Third Quarter 2013 Investor Call on November 12, 2013

ANN ARBOR, Mich., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
01. November 2013 12:10 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Announces Results of Two Studies of Ixmyelocel-T Published in Stem Cell Research & Therapy

ANN ARBOR, Mich., Nov. 1, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
31. Oktober 2013 09:00 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences Regains Compliance With NASDAQ Minimum Bid Requirement

ANN ARBOR, Mich., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
16. Oktober 2013 09:00 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences One-for-Twenty Reverse Stock Split Now Effective

ANN ARBOR, Mich., Oct. 16, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
10. Oktober 2013 16:15 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences Announces One-for-Twenty Reverse Stock Split

ANN ARBOR, Mich., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
10. Oktober 2013 09:00 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences to Present at the 2013 Stem Cell Meeting on the Mesa Conference

ANN ARBOR, Mich., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
19. September 2013 09:00 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences to Present at the Aegis Capital 2013 Healthcare Conference

ANN ARBOR, Mich., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
16. September 2013 09:20 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada

ANN ARBOR, Mich., Sept. 16, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
26. August 2013 16:05 ET | Quelle: Aastrom Biosciences, Inc.

Heidi Hagen Joins Aastrom Board of Directors

ANN ARBOR, Mich., Aug. 26, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
16. August 2013 11:07 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. Announces Closing of Public Offering of Common Stock and Warrants

ANN ARBOR, Mich., Aug. 16, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...

Vorherige Seite

Nächste Seite